{"title":"KLK8：左心室肥厚生物标志物研究的新领域。","authors":"Buqing Cao, Wenhong Yu, Zhihong Diao, Zhenli Ma, Shineng Yan, Lihua Yang, Xiaoqun Huang, Jingmei Yang","doi":"10.1080/17520363.2025.2483153","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the diagnostic potential of serum Kallikrein-related peptidase 8 (KLK8) in detecting left ventricular hypertrophy (LVH).</p><p><strong>Methods: </strong>A total of 62 hypertensive patients with LVH, 60 without LVH, and 60 healthy controls were analyzed. LVH was defined by echocardiography using LVMI thresholds (>95 g/m<sup>2</sup> for females, >115 g/m<sup>2</sup> for males). Serum KLK8 levels were measured via ELISA, and receiver operating characteristic (ROC) curve analysis assessed its diagnostic performance.</p><p><strong>Results: </strong>KLK8 levels were significantly higher in hypertensive patients with LVH (8.59 ± 1.59 ng/mL) than in those without LVH (5.80 ± 1.35 ng/mL) and healthy controls (3.68 ± 0.82 ng/mL). KLK8 positively correlated with blood pressure and cardiac structural parameters, including IVST, LVPWT, and LVEDD. ROC analysis revealed high sensitivity and specificity, indicating KLK8's potential as a biomarker for early LVH detection in hypertension.</p><p><strong>Conclusion: </strong>In hypertensive patients, KLK8 demonstrates good diagnostic value in predicting LVH.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"277-286"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"KLK8: charting new territories in left ventricular hypertrophy biomarker research.\",\"authors\":\"Buqing Cao, Wenhong Yu, Zhihong Diao, Zhenli Ma, Shineng Yan, Lihua Yang, Xiaoqun Huang, Jingmei Yang\",\"doi\":\"10.1080/17520363.2025.2483153\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study investigates the diagnostic potential of serum Kallikrein-related peptidase 8 (KLK8) in detecting left ventricular hypertrophy (LVH).</p><p><strong>Methods: </strong>A total of 62 hypertensive patients with LVH, 60 without LVH, and 60 healthy controls were analyzed. LVH was defined by echocardiography using LVMI thresholds (>95 g/m<sup>2</sup> for females, >115 g/m<sup>2</sup> for males). Serum KLK8 levels were measured via ELISA, and receiver operating characteristic (ROC) curve analysis assessed its diagnostic performance.</p><p><strong>Results: </strong>KLK8 levels were significantly higher in hypertensive patients with LVH (8.59 ± 1.59 ng/mL) than in those without LVH (5.80 ± 1.35 ng/mL) and healthy controls (3.68 ± 0.82 ng/mL). KLK8 positively correlated with blood pressure and cardiac structural parameters, including IVST, LVPWT, and LVEDD. ROC analysis revealed high sensitivity and specificity, indicating KLK8's potential as a biomarker for early LVH detection in hypertension.</p><p><strong>Conclusion: </strong>In hypertensive patients, KLK8 demonstrates good diagnostic value in predicting LVH.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"277-286\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2483153\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2483153","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
KLK8: charting new territories in left ventricular hypertrophy biomarker research.
Objective: This study investigates the diagnostic potential of serum Kallikrein-related peptidase 8 (KLK8) in detecting left ventricular hypertrophy (LVH).
Methods: A total of 62 hypertensive patients with LVH, 60 without LVH, and 60 healthy controls were analyzed. LVH was defined by echocardiography using LVMI thresholds (>95 g/m2 for females, >115 g/m2 for males). Serum KLK8 levels were measured via ELISA, and receiver operating characteristic (ROC) curve analysis assessed its diagnostic performance.
Results: KLK8 levels were significantly higher in hypertensive patients with LVH (8.59 ± 1.59 ng/mL) than in those without LVH (5.80 ± 1.35 ng/mL) and healthy controls (3.68 ± 0.82 ng/mL). KLK8 positively correlated with blood pressure and cardiac structural parameters, including IVST, LVPWT, and LVEDD. ROC analysis revealed high sensitivity and specificity, indicating KLK8's potential as a biomarker for early LVH detection in hypertension.
Conclusion: In hypertensive patients, KLK8 demonstrates good diagnostic value in predicting LVH.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
